EA201590305A1 - Изделие производства, включающее афлиберцепт или зив-афлиберцепт - Google Patents

Изделие производства, включающее афлиберцепт или зив-афлиберцепт

Info

Publication number
EA201590305A1
EA201590305A1 EA201590305A EA201590305A EA201590305A1 EA 201590305 A1 EA201590305 A1 EA 201590305A1 EA 201590305 A EA201590305 A EA 201590305A EA 201590305 A EA201590305 A EA 201590305A EA 201590305 A1 EA201590305 A1 EA 201590305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aflibercept
ziv
production product
biosimilar
notifies
Prior art date
Application number
EA201590305A
Other languages
English (en)
Inventor
Сильви Ассадуриан
Реми Кастан
Эмманюэлль Магерини
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201590305A1 publication Critical patent/EA201590305A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/70—Containers, packaging elements or packages, specially adapted for particular articles or materials for materials not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Wrappers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к изделию производства, включающему упаковочный материал, полипептид SEQ ID NO: 1, афлиберцепт или зив-афлиберцепт, или его биоаналог, и этикетку, включающую напечатанное сообщение, которое уведомляет предполагаемого потребителя о неблагоприятных явлениях или неблагоприятных реакциях.
EA201590305A 2012-08-02 2013-08-02 Изделие производства, включающее афлиберцепт или зив-афлиберцепт EA201590305A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678983P 2012-08-02 2012-08-02
US201261679490P 2012-08-03 2012-08-03
PCT/EP2013/066299 WO2014020160A1 (en) 2012-08-02 2013-08-02 Article of manufacture comprising aflibercept or ziv-aflibercept

Publications (1)

Publication Number Publication Date
EA201590305A1 true EA201590305A1 (ru) 2015-06-30

Family

ID=48917540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590305A EA201590305A1 (ru) 2012-08-02 2013-08-02 Изделие производства, включающее афлиберцепт или зив-афлиберцепт

Country Status (17)

Country Link
US (2) US20150216795A1 (ru)
EP (1) EP2879694A1 (ru)
JP (1) JP2015526430A (ru)
KR (1) KR20150038297A (ru)
CN (1) CN104853763A (ru)
AR (1) AR091967A1 (ru)
AU (1) AU2013298521A1 (ru)
CA (1) CA2888281A1 (ru)
EA (1) EA201590305A1 (ru)
HK (1) HK1206628A1 (ru)
IL (1) IL236931A0 (ru)
MX (1) MX2015001550A (ru)
SG (1) SG11201500480TA (ru)
TW (1) TW201408316A (ru)
UY (1) UY34962A (ru)
WO (1) WO2014020160A1 (ru)
ZA (1) ZA201500485B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788949C1 (ru) * 2019-12-06 2023-01-26 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2732925T3 (es) 2014-07-18 2019-11-26 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer
CN107922095A (zh) 2015-06-17 2018-04-17 诺维信公司 容器
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
TWI746505B (zh) * 2016-01-25 2021-11-21 法商賽諾菲公司 通過測量血漿生物標記的水平預測疑似患有癌症的患者使用阿柏西普的治療的結果的方法
CA3067847A1 (en) * 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN113164544A (zh) * 2018-10-12 2021-07-23 三钰生物科技股份有限公司 双功能性融合蛋白及其用途
AU2020216368A1 (en) * 2019-01-30 2021-08-12 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112021025438A2 (pt) 2019-12-06 2022-06-21 Regeneron Pharma Composições de proteínas anti-vegf e métodos para produzir as mesmas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200708845B (en) * 2005-03-25 2010-07-28 Regeneron Pharma Vegf antogonist formulations
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788949C1 (ru) * 2019-12-06 2023-01-26 Ридженерон Фармасьютикалз, Инк. Белковые композиции против vegf и способы их получения

Also Published As

Publication number Publication date
ZA201500485B (en) 2017-07-26
MX2015001550A (es) 2015-05-11
TW201408316A (zh) 2014-03-01
AR091967A1 (es) 2015-03-11
UY34962A (es) 2014-02-28
WO2014020160A1 (en) 2014-02-06
IL236931A0 (en) 2015-03-31
EP2879694A1 (en) 2015-06-10
US20180078496A1 (en) 2018-03-22
AU2013298521A1 (en) 2015-02-26
CN104853763A (zh) 2015-08-19
SG11201500480TA (en) 2015-02-27
KR20150038297A (ko) 2015-04-08
JP2015526430A (ja) 2015-09-10
HK1206628A1 (en) 2016-01-15
US20150216795A1 (en) 2015-08-06
CA2888281A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
EA201590305A1 (ru) Изделие производства, включающее афлиберцепт или зив-афлиберцепт
MX2019007024A (es) Proteasas de degradacion de plastico mejoradas.
MX2020006359A (es) Nuevas proteasas y usos de las mismas.
MX2020008823A (es) Proceso para preparar microcapsulas.
MX2019000493A (es) Nuevas esterasas y usos de las mismas.
MX2019000492A (es) Nuevas esterasas y usos de las mismas.
PH12015501320B1 (en) Fragrance materials
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
PH12014502669B1 (en) Therapeutic agent or prophylactic agent for dementia
MX2020010399A (es) 3-epimerasa.
MX2018000064A (es) Composiciones que contienen poblaciones multiples de microcapsulas que comprenden perfume.
MX2014015002A (es) Polipeptidos que tienen actividad de transgalactosilacion.
MX368688B (es) Proteasas modificadas con inteína, su producción y aplicaciones industriales.
MX2015014665A (es) Materiales de fragancias.
MX2014008774A (es) Sistemas de perfume.
GB201211142D0 (en) Microcapsules
TW201612108A (en) Method for forming basic nickel carbonate
MX346404B (es) Encapsulados.
MX2020009712A (es) Proceso para preparar microcapsulas.
MX2016005205A (es) Composiciones de proteina de suero lácteo desnaturalizada con alto contenido protéico, que contienen cmp, productos que las contienen y usos de las mismas.
IN2015MN00027A (ru)
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
IN2014DN07983A (ru)
UA112752C2 (uk) Лікарський засіб та метод блокування утворення або посилення знищення білка p24
MX2015001542A (es) Metodo.